This site is intended for healthcare professionals

Seagen announces long-term results from Tukysa pivotal trial for HER2-positive breast cancer during the 2021 ASCO Annual Meeting.

Read time: 1 mins
Last updated:4th Jun 2021
Published:4th Jun 2021
Seagen Inc. announced that improvements in overall survival (OS) and progression-free survival (PFS) were maintained with long-term follow up from the pivotal HER2CLIMB trial evaluating the addition of Tukysa (tucatinib) to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (MBC) with and without brain metastases.
Condition: Breast Cancer HER2+
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest